Navigation Links
Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
Date:11/15/2010

easing levels of cardiovascular disease in emerging market countries. Our Generx product candidate could potentially be developed as a front-line therapy for patients with coronary artery disease who often do not have access to costly advanced care procedures such as coronary angioplasty and stenting, or cardiac bypass surgery."  

About Generx The Generx™ (alferminogene tadenovec, Ad5FGF-4) product candidate represents a new class of cardiovascular biologics that is being developed to leverage the body's natural healing processes in response to repeated ischemic stress (insufficient blood flow and myocardial oxygen supply due to coronary heart disease).  The natural biologic response to repeated transient ischemia is angiogenesis, the growth of new collateral blood vessels, which is orchestrated by a complex and incompletely understood cascade involving many myocardial-derived growth factors.  These newly-formed vessels can effectively augment blood flow and oxygen delivery to parts of the patient's heart downstream from a blockage in a coronary artery.  In many patients however, including those with recurrent angina, coronary collateral vessel formation is insufficient to meet the heart's needs during stress.  Currently available anti-anginal drugs, which may provide symptomatic relief, are generally designed to alter the oxygen demand of the heart muscle or dilate vessels to temporarily relieve angina.  Generx is an angiogenic therapeutic product candidate that is designed to promote the heart's natural response of collateral growth and to increase blood flow in the microcirculation. In contrast to the transient symptomatic relief by marketed anti-anginal medicines, usually taken several times a day for years, a single administration of Generx aims at modifying the disease by permanent or long-lasting structural changes in the heart.

Researchers believe that central to the biological activity and potential thera
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Reports Third Quarter 2010 Financial Results
2. Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean
3. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
4. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
5. GEN reports on the greening of the life sciences
6. Aware, Inc. Reports Second Quarter 2010 Financial Results
7. GEN reports on rediscovered technology to bolster proteomics research
8. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
9. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
10. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... of Oklahoma biology professor will study the unique bioelectric ... could eventually benefit people,s health. The OU researcher ... energy required to produce the signals used to map ... signals at a rate of 500-600 discharges a second ... the electric fish are extreme, but necessary for survival. ...
(Date:9/19/2014)... evolve for the sake of fairness per se but ... so say Frans de Waal, PhD, and Sarah Brosnan, ... (IA), which is defined as a negative reaction to ... . , Their conclusion comes after the co-authors ... hypothesis that it is the evolution of forestalling partner ...
(Date:9/19/2014)... SHELTON, Conn. , Sept. 19, 2014 Nxt-ID, Inc. ... a biometric authentication company focused on the growing m-commerce market, updates ... and world champion in the lightweight and light middleweight weight classes, ... Yesterday it was announced that Game of Thrones ... and Married with Children star Katey Sagal ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... 2012 A paper to be published on January 3, ... by NHM entomologist Dr. Brian Brown, reveals a new threat ... bees, well-publicized Colony Collapse Disorder (CCD), a syndrome characterized by ... but dangerous phorid fly, which may pose an emerging threat ...
... Unique E. coli Protein May Be Not After ... unique mechanism for utilizing iron may not be after all. ... Genomes, the University of Oklahoma and the University of Utah School ... online journal mBio . The ability to acquire iron ...
... Hydrogen sulfide, a gas notorious for its rotten-egg smell, may ... of scarring proteins in kidney cells, researchers from The University ... Journal of Biological Chemistry. The paper is scheduled ... manufacture of scarring proteins , "There is interest in ...
Cached Biology News:NHM entomologist co-authors new research on parasitic phorid fly, a new threat to honey bees 2News tips from the journal mBio 2News tips from the journal mBio 3Hydrogen sulfide reduces glucose-induced injury in kidney cells 2
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
(Date:9/19/2014)... crop yields to disease risks, the biological characteristics people ... Just as for heightthe textbook example of a complex ... shaped by multiple genetic and environmental influences, making it ... such genes, geneticists typically mate two individuals that differ ... small mouseand then study their descendents, looking for genes ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... its potential to revolutionize the world has attracted ... corporations and small start-ups. The early years of ... projects largely due to the high risks involved, ... budgets earmarked for this evolving technology have been ...
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... Biotechnology Corporation (Nasdaq: GNBT, www.generex.com ) announced today ... the Company and a member of the Company,s Scientific ... the reverse stock split proposal being considered at today,s ... been intimately involved in the drug development world for ...
... University of Hawaii at Manoa,s School of Ocean Earth ... of Sea Disposal Site Hawaii Number 5 (HI-05), a ... approximately 5 miles south of Pearl Harbor, Oahu, Hawaii. ... sidescan sonar and remotely operated underwater vehicles to locate ...
... Therapeutics announced today that its President and Chief ... of the Year by the Pittsburgh Technology Council. ... (Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 ) ... of 50 of southwestern Pennsylvania,s most successful entrepreneurs ...
Cached Biology Technology:Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 2Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 3Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 4University of Hawaii completes 3-year investigation of military munitions sea disposal site 2University of Hawaii completes 3-year investigation of military munitions sea disposal site 3Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year 2
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Recombinant Mouse Wnt-3a...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
... 20 structurally and functionally related BMPs, which ... were originally identified as protein regulators of ... involved in embryogenesis and morphogenesis of various ... differentiation, chemotaxis and apoptosis of various cell ...
Biology Products: